Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

The federal government has announced the results of the latest round of Medicare drug price negotiations: 15 lower drug prices for Medicare to go into effect in 2027. Medicare will get a 71% discount ...

Novo Nordisk NOVO.B2.54%increase; green up pointing triangle filed for U.S. approval of a higher dose of its Wegovy weight-loss injection, with a decision expected within a month or two. The Danish ...

The Centers for Medicare & Medicaid Services announced Nov. 25 that Medicare recipients will pay less for 15 prescription drugs, including popular weight-loss medications Ozempic and Wegovy, asthma ...

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National Priority Voucher (CNPV) program on a higher-dose version of its obesity med ...

Trump and Novo struck a deal earlier this month that Medicare would pay $245 per month for Ozempic and Wegovy under the administration’s attempt to lower US drug costs by tying them to international ...

The new prices will take effect in 2027, and the negotiated prices include a monthly cost of $274 for Novo Nordisk’s (NYSE: NVO) popular GLP-1 drug, semaglutide, sold as Wegovy, Ozempic, and Rybelsus.

The US government said Tuesday it negotiated a 71% discount off of the list price of Novo Nordisk A/S ’s blockbuster drugs Ozempic and Wegovy for patients in Medicare, the federal health insurance ...

Birmingham, Alabama, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Curaechoice, the nation’s #1 leader in No-Cost Benefits Optimization Solutions, announced today that it has selected CVS Caremark at its pharmacy ...

The company that sells Ozempic and Wegovy, drugs known for promoting easy weight loss, is now selling the products at Costco. Novo Nordisk, which manufactures the injectable pen semaglutide drugs for ...

The studies were a setback for the optimistic view that semaglutide and other drugs used in obesity and diabetes treatment could help prevent a number of brain diseases. By Gina Kolata Gina Kolata has ...